NASDAQ:FCSC Fibrocell Science (FCSC) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free FCSC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.00▼$3.0050-Day Range$3.00▼$3.0052-Week Range$1.45▼$3.28VolumeN/AAverage Volume78,673 shsMarket Capitalization$29.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Fibrocell Science alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Fibrocell Science Stock (NASDAQ:FCSC)Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Read More Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. FCSC Stock News HeadlinesFebruary 20, 2024 | forbes.comBest Data Science Bootcamps Online In 2024February 6, 2024 | dailymail.co.ukScience & Tech NewsMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.September 16, 2023 | usnews.comWhat You Need to Know About Becoming a Computer Science MajorApril 7, 2023 | marketwatch.comEpidermolysis Bullosa Therapeutics Market Factual Overview Research Report 2023-2030January 13, 2023 | forbes.comOramed PharmaceuticalsDecember 27, 2022 | thestreet.comFibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment DesignationSee More Headlines Receive FCSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FCSC CUSIPN/A CIK357097 Webfibrocell.com Phone484-713-6000FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E GrowthN/ANet Income$-10,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity23.10% Return on Assets10.56% Debt Debt-to-Equity Ratio0.47 Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$350,000.00 Price / Sales83.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book3.06Miscellaneous Outstanding Shares9,760,000Free FloatN/AMarket Cap$29.28 million OptionableOptionable Beta1.67 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. John Michael Maslowski (Age 44)Pres, CEO & Director Mr. Sean D. Buckley (Age 37)VP of Bus. Admin. & Corp. Sec. Mr. Robert G. PartridgeVP of Global Marketing, Communications and Investor RelationsMs. Michele Mchugh-MazzattaVP of SalesDr. Pierre CompteManaging Director of SwitzerlandKey CompetitorsSpruce BiosciencesNASDAQ:SPRBAlaunos TherapeuticsNASDAQ:TCRTFSD PharmaNASDAQ:HUGESol-Gel TechnologiesNASDAQ:SLGLOrgenesisNASDAQ:ORGSView All Competitors FCSC Stock Analysis - Frequently Asked Questions How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) announced its earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $1.30. The firm earned $21.79 million during the quarter. When did Fibrocell Science's stock split? Fibrocell Science's stock reverse split on the morning of Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Neurotrope (NTRP), Verastem (VSTM), Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX). This page (NASDAQ:FCSC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & CompanyBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fibrocell Science Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.